| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Richard P Wenzel | |
| J Patrick Powell | |||
| P2860 | cites work | Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides | Q39466478 |
| High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections | Q39708441 | ||
| Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections | Q39744021 | ||
| Methicillin-resistant staphylococci | Q41289007 | ||
| Linezolid resistance in a clinical isolate of Staphylococcus aureus | Q43690311 | ||
| Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. | Q43723787 | ||
| Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. | Q43858066 | ||
| Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women | Q44635716 | ||
| Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection | Q44686515 | ||
| Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. | Q44727670 | ||
| Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections | Q45157534 | ||
| In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). | Q46654680 | ||
| Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections | Q46695223 | ||
| Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production | Q46763901 | ||
| A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections | Q46787486 | ||
| In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action | Q46930569 | ||
| Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. | Q53544946 | ||
| An Enzyme from Bacteria able to Destroy Penicillin | Q54138191 | ||
| Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 | ||
| Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department | Q55897489 | ||
| MICROBIOLOGY: Weapons of Microbial Drug Resistance Abound in Soil Flora | Q57077247 | ||
| Vaccine protection against Staphylococcus aureus pneumonia | Q24650703 | ||
| Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections | Q24672937 | ||
| “Celbenin” - resistant Staphylococci | Q24675132 | ||
| Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia | Q28260215 | ||
| Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus | Q28300379 | ||
| STAPHYLOCOCCAL TOXIN. | Q29040204 | ||
| Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections | Q33347869 | ||
| Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus | Q34073487 | ||
| Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome | Q34656266 | ||
| Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California | Q34719851 | ||
| Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection | Q35913984 | ||
| Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent | Q36232492 | ||
| Clinical and laboratory features of community-associated methicillin-resistant Staphylococcus aureus: is it really new? | Q36390527 | ||
| Five cases of bacterial endocarditis after furunculosis and the ongoing saga of community-acquired methicillin-resistant Staphylococcus aureus infections | Q36542356 | ||
| Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections | Q36718474 | ||
| Daptomycin: a review 4 years after first approval | Q36972980 | ||
| Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection | Q37058032 | ||
| Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic | Q37058509 | ||
| Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database | Q37059039 | ||
| Intermediate vancomycin susceptibility in a community-associated MRSA clone | Q37302793 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 299-307 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Antibiotic options for treating community-acquired MRSA. | |
| P478 | volume | 6 |
| Q28475993 | A mapping of drug space from the viewpoint of small molecule metabolism |
| Q42593938 | Antibacterial susceptibility patterns and cross-resistance of methicillin resistant and sensitive staphyloccus aureus isolated from the hospitalized patients in shiraz, iran |
| Q37356539 | Antimicrobial resistance in zoonotic bacteria: lessons learned from host-specific pathogens |
| Q38061168 | Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. |
| Q35715381 | Ceftaroline in complicated skin and skin-structure infections |
| Q60302078 | Community-acquired methicillin-resistant from ST1 lineage harboring a new SCC IV subtype (SCC IVm) containing the gene |
| Q24614464 | Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic |
| Q34040814 | In vitro screening antibacterial activity of Bidens pilosa Linné and Annona crassiflora Mart. against oxacillin resistant Staphylococcus aureus (ORSA) from the aerial environment at the dental clinic |
| Q37460085 | In vivo gene regulation using tetracycline-regulatable systems |
| Q27663178 | Inhibition of Antibiotic-Resistant Staphylococcus aureus by the Broad-Spectrum Dihydrofolate Reductase Inhibitor RAB1 |
| Q27671778 | Inhibition of Bacterial Dihydrofolate Reductase by 6-Alkyl-2,4-diaminopyrimidines |
| Q54333201 | Negative impact of linezolid on human neutrophil functions in vitro. |
| Q37533556 | New antibiotics for the management of complicated skin and soft tissue infections: are they any better? |
| Q34187667 | Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole |
| Q28474630 | Staphylococcus aureus bacteraemia in a tropical setting: patient outcome and impact of antibiotic resistance |
Search more.